Financing, available in multiple tranches over the next three years, could extend the Company’s runway into Q4 2024Transaction will enable Evaxion to advance its next-generation cancer vaccine, EVX-03, towards a Phase 1 clinical trial Copenhagen, DENMARK, Aug. 01, 2023 (GLOBE NEWSWIRE) Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that it has entered into a
Evaxion Biotech: Evaxion announces financing commitments totaling up to USD 20 million with Negma Group finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Evaxion announces financing commitments totaling up to USD 20 million with Negma Group tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Eems Italia Spa announced on Wednesday that it has issued 2.3 million new ordinary shares to Negma Group investment Ltd, following the latter s request for conversion of five bonds. The conversion.
Robotaxi Market worth $45 7 billion by 2030 - Exclusive Report by MarketsandMarkets finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.